Press Release - Provided by Duke University Medical Center
Original Investigations | May 5, 2015
Oral Antiviral Treatment of Hepatitis C Genotype 1 Infection
Author Interview @ JAMA - Daclatasvir, Asunaprevir, and Beclabuvir for HCV Infection With Cirrhosis; These cohort studies describe outcomes for HCV genotype-1 infected patients with and without cirrhosis who were treated with an all-oral antiviral regimen.
Full Text Available @ NATAP
Editorial: Continued Progress Against Hepatitis C Infection
Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis
Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
JAMA
Abstract Free - Full content is available to subscribers only
Oral Antiviral Treatment of Hepatitis C Genotype 1 Infection
Author Interview @ JAMA - Daclatasvir, Asunaprevir, and Beclabuvir for HCV Infection With Cirrhosis; These cohort studies describe outcomes for HCV genotype-1 infected patients with and without cirrhosis who were treated with an all-oral antiviral regimen.
Full Text Available @ NATAP
Editorial: Continued Progress Against Hepatitis C Infection
Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis
Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
JAMA
Abstract Free - Full content is available to subscribers only
No comments:
Post a Comment